Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1990 2
1991 2
1997 4
1998 1
1999 1
2000 2
2001 1
2002 5
2003 6
2004 1
2005 5
2006 5
2007 14
2008 5
2009 4
2010 6
2011 6
2012 8
2013 13
2014 4
2015 15
2016 8
2017 12
2018 14
2019 7
2020 9
2021 9
2022 10
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
Passamonti F, Palandri F, Saydam G, Callum J, Devos T, Guglielmelli P, Vannucchi AM, Zor E, Zuurman M, Gilotti G, Zhang Y, Griesshammer M. Passamonti F, et al. Among authors: saydam g. Lancet Haematol. 2022 Jul;9(7):e480-e492. doi: 10.1016/S2352-3026(22)00102-8. Epub 2022 May 18. Lancet Haematol. 2022. PMID: 35597252 Clinical Trial.
Ocular Adnexal Lymphomas: Single-Center Experience.
Özkan MC, Palamar M, Tombuloğlu M, Hekimgil M, Özsan N, Saydam G, Şahin F. Özkan MC, et al. Among authors: saydam g. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S158-60. doi: 10.1016/j.clml.2015.02.015. Clin Lymphoma Myeloma Leuk. 2015. PMID: 26297270 Review.
Pesg PNH diagnosis, follow-up and treatment guidelines.
Sahin F, Akay OM, Ayer M, Dal MS, Ertop S, Ilhan O, Karakus V, Ozcan MA, Ozkocaman V, Ozsan H, Salim O, Tobu M, Tombak A, Tuglular TF, Yilmaz M, Unal A, Yenerel MN, Saydam G. Sahin F, et al. Among authors: saydam g. Am J Blood Res. 2016 Aug 5;6(2):19-27. eCollection 2016. Am J Blood Res. 2016. PMID: 27570707 Free PMC article. Review.
Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria.
Sahin F, Ozkan MC, Mete NG, Yilmaz M, Oruc N, Gurgun A, Kayikcioglu M, Guler A, Gokcay F, Bilgir F, Ceylan C, Bilgir O, Sari IH, Saydam G. Sahin F, et al. Among authors: saydam g. Am J Blood Res. 2015 Jun 15;5(1):1-9. eCollection 2015. Am J Blood Res. 2015. PMID: 26171279 Free PMC article. Review.
Peripheral blood stem cell mobilization from healthy donors.
Ozkan MC, Sahin F, Saydam G. Ozkan MC, et al. Among authors: saydam g. Transfus Apher Sci. 2015 Aug;53(1):13-6. doi: 10.1016/j.transci.2015.05.008. Epub 2015 May 19. Transfus Apher Sci. 2015. PMID: 26043813 Review.
Granulocytic sarcoma: a systematic review.
Yilmaz AF, Saydam G, Sahin F, Baran Y. Yilmaz AF, et al. Among authors: saydam g. Am J Blood Res. 2013 Dec 18;3(4):265-70. Am J Blood Res. 2013. PMID: 24396704 Free PMC article. Review.
Primary testicular lymphoma.
Vural F, Cagirgan S, Saydam G, Hekimgil M, Soyer NA, Tombuloglu M. Vural F, et al. Among authors: saydam g. J Natl Med Assoc. 2007 Nov;99(11):1277-82. J Natl Med Assoc. 2007. PMID: 18020104 Free PMC article.
The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Saydam G, Ali R, Demir AM, Eskazan AE, Guvenc B, Haznedaroglu IC, Ozcan MA, Salim O, Sonmez M, Tuglular AT, Turgut M, Unal A, Aver B, Bozkurt S, Ozdengulsun B, Ilhan O. Saydam G, et al. Int J Hematol Oncol. 2022 May 24;11(1):IJH38. doi: 10.2217/ijh-2021-0010. eCollection 2022 Mar. Int J Hematol Oncol. 2022. PMID: 35664044 Free PMC article. Review.
169 results